ABSTRACT
OBJECTIVE: To determine the prevalence of JC virus (JCV) reactivation and JCV-specific cellular immune response during prolonged natalizumab treatment for multiple sclerosis (MS). METHODS: We enrolled 43 JCV-seropositive MS patients, including 32 on natalizumab monotherapy >18 months, 6 on interferon ß-1a monotherapy >36 months, and 5 untreated controls. We performed quantitative real-time polymerase chain reaction in cerebrospinal fluid (CSF), blood, and urine for JCV DNA, and we determined JCV-specific T-cell responses using enzyme-linked immunosorbent spot (ELISpot) and intracellular cytokine staining (ICS) assays, ex vivo and after in vitro stimulation with JCV peptides. RESULTS: JCV DNA was detected in the CSF of 2 of 27 (7.4%) natalizumab-treated MS patients who had no symptoms or magnetic resonance imaging-detected lesions consistent with progressive multifocal leukoencephalopathy. JCV DNA was detected in blood of 12 of 43 (27.9%) and in urine of 11 of 43 (25.6%) subjects without a difference between natalizumab-treated patients and controls. JC viral load was higher in CD34(+) cells and in monocytes compared to other subpopulations. ICS was more sensitive than ELISpot. JCV-specific T-cell responses, mediated by both CD4(+) and CD8(+) T lymphocytes, were detected more frequently after in vitro stimulation. JCV-specific CD4(+) T cells were detected ex vivo more frequently in MS patients with JCV DNA in CD34(+) (p = 0.05) and B cells (p = 0.03). INTERPRETATION: Asymptomatic JCV reactivation may occur in CSF of natalizumab-treated MS patients. JCV DNA load is higher in circulating CD34(+) cells and monocytes compared to other mononuclear cells, and JCV in blood might trigger a JCV-specific CD4(+) T-cell response. JCV-specific cellular immune response is highly prevalent in all JCV-seropositive MS patients, regardless of treatment.
Subject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , Immunologic Factors/therapeutic use , Multiple Sclerosis/drug therapy , Adult , Aged , DNA, Viral/blood , DNA, Viral/cerebrospinal fluid , DNA, Viral/urine , Enzyme-Linked Immunosorbent Assay , Female , Follow-Up Studies , Humans , Interferon beta-1a , Interferon-beta/therapeutic use , Interferon-gamma/metabolism , JC Virus/genetics , Male , Middle Aged , Multiple Sclerosis/complications , Multiple Sclerosis/epidemiology , Multiple Sclerosis/virology , Natalizumab , Polyomavirus Infections/complications , Polyomavirus Infections/epidemiology , Retrospective Studies , Statistics as Topic , T-Lymphocytes/metabolism , Time FactorsSubject(s)
Antibodies, Monoclonal/therapeutic use , Immunologic Factors/therapeutic use , JC Virus , Multiple Sclerosis/drug therapy , Multiple Sclerosis/immunology , Antibodies, Monoclonal, Humanized , Antigens/metabolism , Humans , Interferon-beta/therapeutic use , JC Virus/metabolism , Multiple Sclerosis/metabolism , Natalizumab , T-Lymphocytes/metabolismSubject(s)
Antineoplastic Agents/adverse effects , Carcinoma, Hepatocellular/drug therapy , Gait Disorders, Neurologic/chemically induced , Indoles/adverse effects , Liver Neoplasms/drug therapy , Postural Balance/drug effects , Pyrroles/adverse effects , Aged , Carcinoma, Hepatocellular/complications , Clinical Trials, Phase III as Topic , Gait Disorders, Neurologic/physiopathology , Hepatitis, Autoimmune/complications , Humans , Liver Neoplasms/complications , Male , Protein Kinase Inhibitors/adverse effects , Protein-Tyrosine Kinases/antagonists & inhibitors , Protein-Tyrosine Kinases/drug effects , Sensation Disorders/chemically induced , SunitinibABSTRACT
BACKGROUND: Progressive multifocal leukoencephalopathy (PML) occurs in a fraction of patients with multiple sclerosis who were treated with natalizumab. Most adults who are infected with the JC virus, the etiologic agent in PML, do not have symptoms. We sought to determine whether exposure to natalizumab causes subclinical reactivation and neurotropic transformation of JC virus. METHODS: We followed 19 consecutive patients with multiple sclerosis who were treated with natalizumab over an 18-month period, performing quantitative polymerase-chain-reaction assays in blood and urine for JC virus reactivation; BK virus, a JC virus-related polyomavirus, was used as a control. We determined JC virus-specific T-cell responses by means of an enzyme-linked immunospot assay and antibody responses by means of an enzyme-linked immunosorbent assay and analyzed JC virus regulatory-region sequences. RESULTS: After 12 months of natalizumab therapy, the prevalence of JC virus in the urine of the 19 patients increased from a baseline value of 19% to 63% (P=0.02). After 18 months of treatment, JC virus was detectable in 3 of 15 available plasma samples (20%) and in 9 of 15 available samples of peripheral-blood mononuclear cells (60%) (P=0.02). JC virus regulatory-region sequences in blood samples and in most of the urine samples were similar to those usually found in PML. Conversely, BK virus remained stable in urine and was undetectable in blood. The JC virus-specific cellular immune response dropped significantly between 6 and 12 months of treatment, and variations in the cellular immune response over time tended to be greater in patients in whom JC viremia developed. None of the patients had clinical or radiologic signs of PML. CONCLUSIONS: Subclinical reactivation of JC virus occurs frequently in natalizumab-treated patients with multiple sclerosis. Viral shedding is associated with a transient drop in the JC virus-specific cellular immune response.
Subject(s)
Antibodies, Monoclonal/adverse effects , Integrin alpha4/immunology , JC Virus/physiology , Leukoencephalopathy, Progressive Multifocal/chemically induced , Multiple Sclerosis, Relapsing-Remitting/drug therapy , Virus Activation/drug effects , Adult , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Humanized , Antibodies, Viral/blood , DNA, Viral/blood , Female , Humans , JC Virus/genetics , JC Virus/immunology , JC Virus/isolation & purification , Male , Middle Aged , Multiple Sclerosis, Relapsing-Remitting/complications , Natalizumab , Pilot Projects , Urine/virology , Viral Load , Viremia/diagnosis , Young AdultSubject(s)
Aquaporin 4/immunology , Autoantibodies/blood , Autoantigens/immunology , Myelitis, Transverse/diagnosis , Optic Neuritis/diagnosis , Adult , Brain/pathology , Female , Follow-Up Studies , Glucocorticoids/therapeutic use , Humans , Immunoglobulin G/analysis , Infusions, Intravenous , Magnetic Resonance Imaging , Methylprednisolone Hemisuccinate/therapeutic use , Myelitis, Transverse/drug therapy , Myelitis, Transverse/immunology , Optic Neuritis/drug therapy , Optic Neuritis/immunology , RecurrenceABSTRACT
We sought to compare the ongoing CD8+ cytotoxic T lymphocytes (CTL) immune response of MS patients to self and viral antigens. Using 51Cr release and tetramer staining assays, we found that the CTL response against VP1, the major capsid protein of the polyomavirus JC (JCV), was significantly higher than the one against epitopes of MBP and PLP. The JCV-specific CTL response was also significantly stronger in MS patients than healthy control subjects. These findings may shed a new light on the recent events related to the development of progressive multifocal leukoencephalopathy in three natalizumab-treated patients.